PRINCETON JUNCTION, N.J., Nov. 16 /PRNewswire/ -- EDDA Technology today
announced that it has received clearance from the U.S. Food and Drug
Administration (FDA) to market its IQQA(R)-Liver software, an image
analysis system that provides diagnostic decision support for physicians'
evaluation of hepatic lesions using multiphase Multi-Detector CT (MDCT).
IQQA(R)-Liver is the first diagnostic analysis system that provides
real-time decision support for managing four dimensional patient liver
image data (3 spatial dimensions, plus time). With the recent advances in
MDCT and dynamic imaging, early detection and treatment planning of liver
diseases has been significantly enhanced. However, with these advances
comes the challenge of efficiently dealing with a tremendous increase in
image data. With a typical multiphase liver study generating several
hundred CT images, there has never been a more urgent need for radiologists
to have access to tools that can support them in making more efficient and
effective diagnoses.
Combining advanced image analysis algorithms and powerful visualization
tools, IQQA(R)-Liver supports clinical workflow for physicians to quickly
and effectively distill critical diagnostic information from image data
sets of extraordinary size. The software performs automatic, anatomic phase
registration to allow simultaneous visualization and easy cross-referencing
of lesion location and features across the different phases.
IQQA(R)-Liver further provides segmentation and measurement tools for
the visualization and analysis of liver lesions, hepatic vascular
structures, as well as liver lobes. This volumetric analysis not only
provides physicians with a powerful visualization aid, but also offers
quantification tools to support their clinical decision making and patient
care management.
"EDDA is committed to innovation, and to improving early detection,
early diagnosis and precise treatment of lethal diseases through
development of the most advanced computer technologies," says Dr.
Jian-Zhong Qian, President and CEO of EDDA Technology. "Following EDDA's
debut product IQQA(R)-Chest software for early lung lesion detection,
IQQA(R)-Liver is another important step forward in this direction. We will
continue our efforts to provide our customers with the new generation of
diagnostic decision supporting solutions."
Liver disease is among the 10 major causes of death in the US,
according to the American Liver Foundation. There are 25,000,000 Americans
afflicted by liver disease. Primary liver cancer, an extreme type of
malignancy that starts in the liver, is one of the most common malignancies
in the world, with approximately 1,000,000 cases reported every year. This
ranges from 16,000 new cases in the US to 500,000 in China. Liver
metastasis tumors also occur frequently, as any primary cancer location can
deposit metastases in the liver. As the liver is generally the first site
of metastatic spread, aggressive surgical intervention at an early stage of
metastasis results in a reported 25-40% five-year survival rate.
The IQQA(R)-Liver software has also been approved by the Chinese State
Food and Drug Administration for marketing and production. It has been in
clinical use in several luminary Chinese hospitals for liver cancer
detection, diagnosis and treatment planning purposes, including Eastern
Hepatobiliary Surgery Hospital in Shanghai, and Peking Union Medical
College Hospital in Beijing.
EDDA Technology will feature IQQA(R)-Liver at the upcoming 92nd
Scientific Assembly and Annual Meeting of the Radiological Society of North
America (RSNA). RSNA 2006 will also provide the occasion for EDDA to
showcase IQQA(R)-Chest Enterprise. IQQA(R)-Chest has clinically
demonstrated an ability to improve radiologists' detection of small lung
nodules (5-15mm) up to 85 percent. The new Enterprise version addresses the
accessibility challenge for advanced clinical applications and provides a
unique enabling solution capable of instantly deploying the full
functionality of the IQQA(R)-Chest application on existing PACS review
consoles without additional requirement or setup effort on the PACS
workstations. IQQA(R)-Chest carries the CE mark, and has clearance from the
U.S. FDA, and Chinese SFDA.
About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution
provider in diagnostic imaging and analysis. EDDA offers a series of new
generation software products to enable early detection of diseases and
enhance precision in diagnosis. EDDA's goal is to deliver advanced
information analysis technologies that improve clinical workflow and
accuracy with broad accessibility. A privately held Delaware corporation,
EDDA is headquartered in Princeton Junction, New Jersey, and has a regional
office in Shanghai, China. In April 2006, EDDA entered into a strategic
partnership with Philips Medical Systems to provide advanced digital
radiography solutions to assist in the detection of lung lesions. IQQA is a
registered trademark of EDDA Technology. For further information, please
log on to http://www.edda-tech.com, or contact info@edda-tech.com or call
609-936-8282.
Editor's Note: EDDA Technology will be exhibiting their IQQA(R) Family
of Products in Booth # 3271 in the South Hall of McCormick Place at the
92nd Scientific Assembly and Annual Meeting of the Radiological Society of
North America (RSNA), Nov. 26 - Dec. 1, 2006.
SOURCE EDDA Technology, Inc.
 back to top
Related links:
http://www.edda-tech.com
CONTACT:
Xiaolan Zeng of EDDA Technology,
+1-609-936-8282 x106, info@edda-tech.com
|
